Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 10 for:    LGMD2I

Open Label Phase 2 Study of BBP-418 in Patients With LGMD2I

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04800874
Recruitment Status : Enrolling by invitation
First Posted : March 16, 2021
Last Update Posted : July 12, 2021
Sponsor:
Information provided by (Responsible Party):
ML Bio Solutions, Inc.

Brief Summary:
BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). This is an open label study to determine the safety and tolerability of ascending dose levels of BBP-418 in the treatment of ambulatory and non-ambulatory patients with LGMD2I for which no approved therapy currently exists.

Condition or disease Intervention/treatment Phase
LGMD2I Drug: BBP-418 Phase 2

Detailed Description:
This is an open label study in ambulatory and non-ambulatory subjects with LGMD2I (also known as LGMD R9) previously enrolled in the natural history Study MLB-01-001. This is a study to determine the safety and tolerability of ascending dose levels of BBP-418 in those subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Subjects must have been enrolled in the MLB-01-001 study to participate in this trial. Three ascending dose cohorts of 4-6 subjects each are planned.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Phase 2 Study of BBP-418 in Patients With Limb Girdle Muscular Dystrophy Type 2I (MLB-01-003)
Actual Study Start Date : February 18, 2021
Estimated Primary Completion Date : October 1, 2023
Estimated Study Completion Date : August 1, 2026


Arm Intervention/treatment
Experimental: Cohort 1
Subjects will receive 6 grams of BBP-418 once daily x 90 days, then 12 grams twice daily (BID, a least 8 hours apart) of BBP-418 daily until study completion.
Drug: BBP-418
BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) for which no approved therapy currently exists. It targets the molecular defect at the source by supplying excess substrate to the mutant enzyme thus boosting glycosylation of muscle α-dystroglycan. The BBP-418 drug product will be packaged in sachets and provided in a carton for in-clinic and at home use.

Experimental: Cohort 2
Subjects will receive 6 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
Drug: BBP-418
BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) for which no approved therapy currently exists. It targets the molecular defect at the source by supplying excess substrate to the mutant enzyme thus boosting glycosylation of muscle α-dystroglycan. The BBP-418 drug product will be packaged in sachets and provided in a carton for in-clinic and at home use.

Experimental: Cohort 3
Subjects will receive 12 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
Drug: BBP-418
BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) for which no approved therapy currently exists. It targets the molecular defect at the source by supplying excess substrate to the mutant enzyme thus boosting glycosylation of muscle α-dystroglycan. The BBP-418 drug product will be packaged in sachets and provided in a carton for in-clinic and at home use.




Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (TEAEs) that lead to dose decrease or discontinuation [ Time Frame: 27 months ]

Secondary Outcome Measures :
  1. Pharmacokinetic profile of BBP-418 by assessment of maximum concentration (Cmax) [ Time Frame: 27 months ]
  2. Changes in pharmacodynamic parameters by assessing changes in levels of N-terminal fragment of alpha dystroglycan (α-DG) [ Time Frame: 27 months ]
  3. Changes in pharmacodynamic parameters by assessing muscle biopsy of the tibialis anterior [ Time Frame: 27 months ]
  4. Pharmacokinetic profile of BBP-418 by assessment of area under the curve (AUC) [ Time Frame: 27 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 55 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have a body weight >30 kg
  • Have a genetically confirmed diagnosis of LGMD2I and be clinically affected (defined as demonstrating clinical weakness on bedside evaluation in either a limb-girdle pattern, or in a distal extremity)
  • Able to complete the 10-meter walk test in ≤ 12 seconds unaided ("moderate disease") or are with "severe disease"/non-ambulatory as defined by being unable to complete the 10-meter walk unaided in >12 seconds
  • Willing to use an adequate method of contraception from time of consent through 12 weeks after last dose
  • Previous enrolment in the Natural History study MLB-01-001

Exclusion Criteria:

  • Evidence of clinically significant concomitant disease, including:

    • Any history of a gastrointestinal condition, including surgeries, which may affect absorption after oral administration
    • Any significant concomitant medical condition, including cardiac, pulmonary, renal, hepatic or endocrine disease other than that associated with LGMD2I
    • Any condition other than LGMD2I requiring therapy with prescription medicine (medication for common and mild concomitant conditions may be permitted after consultation with the PI)
    • Any other laboratory, vital sign, ECG abnormality, or clinical history or finding that, in the investigator's opinion, is likely to unfavorably alter the risk-benefit of study participation, confound study results, or interfere with study conduct or compliance
  • If pregnant, planning to become pregnant and/or breastfeeding or planning to conceive children within the projected duration of the study through 12 weeks after the last dose of study treatment.
  • History of drug abuse including alcoholism within 2 years prior to consenting
  • Use of ribose or other sugar alcohol-containing supplement within 60 days of Day 1
  • Use of a corticosteroid within 60 days of Day 1
  • Presence of a platelet disorder, bleeding disorder or other contraindication to muscle biopsy
  • Actively on an experimental therapy or device or was on an experimental therapy or device within 60 days prior to Day 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04800874


Locations
Layout table for location information
United States, Virginia
Virginia Commonwealth University
Richmond, Virginia, United States, 23219
Sponsors and Collaborators
ML Bio Solutions, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Amy Harper, MD Virginia Commonwealth University
Layout table for additonal information
Responsible Party: ML Bio Solutions, Inc.
ClinicalTrials.gov Identifier: NCT04800874    
Other Study ID Numbers: MLB-01-003
First Posted: March 16, 2021    Key Record Dates
Last Update Posted: July 12, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ML Bio Solutions, Inc.:
LGMD
LGMD R9
Limb Girdle Muscular Dystrophy